806 reports of this reaction
1.1% of all BOTULINUM TOXIN TYPE A reports
#16 most reported adverse reaction
GASTROOESOPHAGEAL REFLUX DISEASE is the #16 most commonly reported adverse reaction for BOTULINUM TOXIN TYPE A, manufactured by Galderma Laboratories, L.P.. There are 806 FDA adverse event reports linking BOTULINUM TOXIN TYPE A to GASTROOESOPHAGEAL REFLUX DISEASE. This represents approximately 1.1% of all 74,480 adverse event reports for this drug.
Patients taking BOTULINUM TOXIN TYPE A who experience gastrooesophageal reflux disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GASTROOESOPHAGEAL REFLUX DISEASE is a less commonly reported adverse event for BOTULINUM TOXIN TYPE A, but still significant enough to appear in the safety profile.
In addition to gastrooesophageal reflux disease, the following adverse reactions have been reported for BOTULINUM TOXIN TYPE A:
The following drugs have also been linked to gastrooesophageal reflux disease in FDA adverse event reports:
GASTROOESOPHAGEAL REFLUX DISEASE has been reported as an adverse event in 806 FDA reports for BOTULINUM TOXIN TYPE A. This does not prove causation, but indicates an association observed in post-market surveillance data.
GASTROOESOPHAGEAL REFLUX DISEASE accounts for approximately 1.1% of all adverse event reports for BOTULINUM TOXIN TYPE A, making it a notable side effect.
If you experience gastrooesophageal reflux disease while taking BOTULINUM TOXIN TYPE A, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.